

# AVANTAGE - Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Head :Medical data center

Last update : 02/04/2022 | Version : 1 | ID : 74114

## General

### Identification

Detailed name Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Sign or acronym AVANTAGE

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation

ML28621

### General Aspects

Medical area Cancer research

Study in connection with Covid-19 No

Pathology (details) Non-squamous non-small cell lung cancer

Health determinants Medicine

Keywords Bevacizumab

### Scientific investigator(s) (Contact)

Name of the director Medical data center

Email data\_sharing\_france@roche.com

Organization Roche SAS

### Collaborations

Participation in projects, networks and consortia No

## Funding

Funding status Private

## Governance of the database

Sponsor(s) or organisation(s) responsible Roche SAS

Organisation status Private

Presence of scientific or steering committees Yes

## Additional contact

## Main features

### Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is carried out as part of an interventional study No

## Database objective

Main objective

In each cohort of patients defined by their age classification ([65; 70[ and  $\geq 70$  years), outcome measures are as follows:

- Antineoplastic agents combined with bevacizumab as 1st line therapy
- Classes of antineoplastic agents combined with bevacizumab as 1st line therapy (platinum salt, taxanes,...)
- Supportive care (growth factors, analgesics).

to describe:

- Characteristics of advanced nsNSCLC patients treated with bevacizumab as first-line therapy, and their disease characteristics,
- Progression-Free Survival (PFS) and Overall Survival (OS),
- Evolution of patients' quality of life over the treatment period with bevacizumab as first-line therapy,
- Safety of bevacizumab,

- Reasons for non-use of bevacizumab as first-line therapy in patients suffering from advanced nsNSCLC.

#### Inclusion criteria

Inclusion criteria :

- Patient aged  $\geq$  65 years,
- Diagnosed with advanced nsNSCLC (stage IIIB or IV),
- For whom the physician has decided to initiate a treatment with bevacizumab combined with chemotherapy as 1st line therapy,
- Having received oral and written information about the study, and having signed a written consent form.

#### Population type

Age

Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered

Sick population

Pathology

C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue

Gender

Male  
Woman

Geography area

National

#### Data collection

#### Dates

Date of first collection (YYYY or MM/YYYY)

2013

Date of last collection (YYYY or MM/YYYY)

2017

#### Size of the database

Size of the database (number of individuals)

< 500 individuals

Details of the number of individuals

277

#### Data

Database activity

Data collection completed

Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Validation of selection criteria ; Information about the study and written consent form ; Demographic and general data ; Disease history ; Bevacizumab treatment ; G8 index and comorbidity index of Charlson, if done ; Response to first-line treatment ; Combined treatments ; First disease progression ; Patient-reported outcomes ; Reason of withdrawal ; Adverse events.
Presence of a biobank	No
<b>Procedures</b>	
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Followed pathology	C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
Links to administrative sources	No
<b>Promotion and access</b>	
<b>Promotion</b>	
<b>Access</b>	
Dedicated website	<a href="https://www. Roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html">https://www. Roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html</a>
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only